Actos (pioglitazone) reduces the risk of heart attack, stroke, and death in some patients with type 2 diabetes

October 2005

New evidence shows that Actos (pioglitazone) reduces the risk of heart attack, stroke, and death in some patients with type 2 diabetes.

We know that improving glycemic control reduces the risk of MICROvascular complications...retinopathy, nephropathy, neuropathy.

But there are questions about whether improving glycemic control reduces MACROvascular complications...heart attack and stroke.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote